So, you want to invest in AbbVie (ABBV 2.33%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

Among patients treated with delgocitinib cream who had an IGA-CHE score of ... Disclosures: Armstrong reports financial relationships with AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS ...

Elahere secured full approval from the US Food and Drug Administration last year. Credit: © AbbVie. US-based pharmaceutical company AbbVie has reported the final ...

“Ruxolitinib cream may be a novel approach for the treatment ... Kwatra disclosed financial relationships with Incyte Corporation, along with AbbVie, Amgen, Arcutis Biotherapeutics, ASLAN ...

Mirvetuximab soravtansine-gynx shows superior progression-free and overall survival in FRα+, platinum-resistant ovarian cancer compared to chemotherapy. The treatment achieved a higher objective ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...